NCT05405465View on ClinicalTrials.gov

Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions

Ulcerative ColitisFlare Up, Symptom

Interventions

DRUG

Exposure to golimumab

Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.

Trial Locations (1)

8091

Division of Gastroenterology, University Hospital Zurich, Zurich

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Zurich

OTHER

NCT05405465 - Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland | Biotech Hunter | Biotech Hunter